OncoBLAZE LLC Awarded NSF STTR Phase I Grant to Advance Groundbreaking Precision Chemotherapy Technology
OncoBLAZE LLC, an innovative startup from the Medical University of South Carolina, has been awarded $275,000 Phase I Small Business Technology Transfer (STTR) grant by the National Science Foundation (NSF). This grant will support the development of their groundbreaking precision chemotherapy delivery technology to prevent cancer recurrence after surgery.
OncoBLAZE’s cutting-edge technology combines a thermo-sensitive liposomal drug with a precision heat source to eliminate the residual cancer cells left behind after surgical procedures. This
innovative technique has the potential to drastically reduce the likelihood of cancer regrowth offering a potential cure to cancer patients who would otherwise face the risk of relapse.
“This NSF STTR Phase I grant, not only propels our technology closer to human application but also validates our approach through the rigorous peer-review process,” said Dr. Dieter Haemmerich, CEO of OncoBLAZE. “Our team has been exploring the use of thermo-sensitive drugs for decades> We believe this novel solution could revolutionize post-surgery cancer treatments by effectively eradicating residual cancer cells.”
Economic Impact and Collaborative Growth
The NSF grant will also drive local economic growth by enabling OncoBLAZE to hire additional employees in South Carolina and solidifying its partnership with the Medical University of South Carolina (MUSC), which will perform part of the grant project through a subcontract.
This milestone aligns closely with the goals of the Economic Development Administration (EDA), enhancing job creation and fostering scientific advancement. By expanding its workforce and deepening ties with both academic and industrial partners, OncoBLAZE is contributing to South Carolina’s economic development and positioning itself at the forefront of cancer treatment innovation.
For more Information please contact:
Dieter Haemmerich, CEO
About OncoBLAZE LLC
Established in 2023, OncoBLAZE is dedicated to advancing cancer therapies through precision chemotherapy delivery. Headquartered in Charleston, South Carolina, the company is committed to developing innovative solutions that address the significant challenges of cancer recurrence post-surgery. With strong partnerships in academia and industry, OncoBLAZE is poised to make a substantial impact in cancer treatment and the biotechnology sector.